| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
16,920,000 |
| Market
Cap: |
2.77(M) |
| Last
Volume: |
25,688,722 |
Avg
Vol: |
24,206,070 |
| 52
Week Range: |
$0.164 - $0.164 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Windtree Therapeutics is a clinical-stage, biopharmaceutical company focused on the development of therapeutics to address unmet medical needs in acute care markets. Co.'s primary product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients with acute heart failure. In addition, Co. cardiovascular drug product candidates include rostafuroxin, for the treatment of hypertension in patients with a specific genetic profile. Co.'s pulmonary product candidate portfolio consists of a KL4 surfactant platform to address a range of serious respiratory conditions in children and adults.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,500 |
24,812 |
| Total Buy Value |
$0 |
$0 |
$2,250 |
$15,204 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
1 |
8 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Curtis Eric |
SVP & COO |
• • – |
2020-10-08 |
4 |
B |
$5.27 |
$2,635 |
D/D |
500 |
500 |
2.66 |
-1% |
|
| Hamill John P. |
SVP & CFO |
• • – |
2020-10-07 |
4 |
B |
$5.27 |
$5,270 |
D/D |
1,000 |
1,000 |
2.74 |
6% |
|
| Fraser Craig |
President and CEO |
• • – |
2020-10-07 |
4 |
B |
$5.17 |
$1,293 |
D/D |
250 |
23,798 |
2.73 |
6% |
|
| Huang James |
Director |
• • • |
2020-06-04 |
4/A |
B |
$7.32 |
$87,868 |
D/D |
12,000 |
20,000 |
3.92 |
- |
|
| Huang James |
Director |
• • • |
2020-06-04 |
4 |
B |
$7.32 |
$89,332 |
D/D |
12,200 |
20,200 |
3.92 |
-15% |
|
| Huang James |
Director |
• • • |
2020-06-03 |
4 |
B |
$7.42 |
$1,484 |
D/D |
200 |
8,000 |
3.84 |
-13% |
|
| Templeton Mary B Esq |
SVP, Gen Counsel & Corp Sec |
• • – |
2020-05-22 |
4 |
B |
$7.25 |
$7,997 |
D/D |
1,103 |
1,134 |
2.74 |
-24% |
|
| Mahady Joseph M |
Director |
• • – |
2020-05-22 |
4 |
B |
$7.25 |
$15,000 |
D/D |
2,069 |
7,455 |
2.39 |
-24% |
|
| Tattory John Andrew |
SVP & CFO |
• • – |
2020-05-22 |
4 |
B |
$7.25 |
$3,255 |
D/D |
449 |
9,280 |
2.66 |
-24% |
|
| Schreiber Brian D |
Director |
• • – |
2020-05-22 |
4 |
B |
$7.25 |
$15,000 |
D/D |
2,069 |
2,069 |
2.39 |
-24% |
|
| Simonson Steven |
SVP, Chief Medical Officer |
• • – |
2020-05-22 |
4 |
B |
$7.25 |
$3,748 |
D/D |
517 |
10,802 |
2.66 |
-24% |
|
| Peacock Bruce |
Director |
• • – |
2020-05-22 |
4 |
B |
$7.25 |
$25,375 |
D/D |
3,500 |
8,886 |
2.39 |
-24% |
|
| Geffken Daniel E |
Director |
• • – |
2020-05-22 |
4 |
B |
$7.25 |
$15,000 |
D/D |
2,069 |
2,069 |
2.39 |
-24% |
|
| Leone John R |
Director |
• • – |
2020-05-22 |
4 |
B |
$7.25 |
$15,000 |
D/D |
2,069 |
7,473 |
2.39 |
-24% |
|
| Fraser Craig |
President and CEO |
• • – |
2020-05-22 |
4 |
B |
$7.25 |
$15,000 |
D/D |
2,069 |
23,548 |
2.81 |
-24% |
|
| Huang James |
Director |
• • • |
2020-05-22 |
4 |
B |
$7.25 |
$2,000,000 |
I/I |
275,862 |
2,336,853 |
2.25 |
-24% |
|
| Center Laboratories, Inc. |
10% Owner |
– – • |
2020-05-20 |
4 |
B |
$7.25 |
$399,997 |
I/I |
55,172 |
1,239,088 |
1.5 |
-21% |
|
| Center Laboratories, Inc. |
10% Owner |
– – • |
2020-05-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,551,750) |
1,183,916 |
|
- |
|
| Bioengine Capital Inc. |
10% Owner |
– – • |
2020-05-20 |
4 |
B |
$7.25 |
$399,997 |
D/D |
55,172 |
1,239,088 |
2.45 |
-21% |
|
| Bioengine Capital Inc. |
10% Owner |
– – • |
2020-05-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,551,750) |
1,183,916 |
|
- |
|
| Huang James |
Director |
• • • |
2020-02-18 |
4 |
B |
$3.84 |
$1,535 |
D/D |
400 |
23,400 |
3.84 |
-42% |
|
| Fraser Craig |
President and CEO |
• • – |
2020-02-11 |
4 |
B |
$4.10 |
$1,025 |
D/D |
250 |
63,590 |
2.73 |
-43% |
|
| Fraser Craig |
President and CEO |
• • – |
2020-02-10 |
4 |
B |
$4.10 |
$1,025 |
D/D |
250 |
63,340 |
2.73 |
-43% |
|
| Huang James |
Director |
• • • |
2020-02-07 |
4 |
B |
$4.05 |
$2,025 |
D/D |
500 |
23,000 |
3.84 |
-49% |
|
| Fraser Craig |
President and CEO |
• • – |
2020-02-04 |
4 |
B |
$4.24 |
$2,120 |
D/D |
500 |
63,090 |
2.73 |
-39% |
|
619 Records found
|
|
Page 3 of 25 |
|
|
